Abstract
Background: The aim of this study was to investigate the prognostic significance of faciogenital dysplasia 6 (FGD6) in gastric cancer (GC).Methods: The data of GC patients from The Cancer Genome Atlas (TCGA) database were used for the primary study. Then, our data were validated by the GEO database and RuiJin cohort. The relationship between the FGD6 level and various clinicopathological features was analyzed by logistic regression and univariate Cox regression. Multivariate Cox regression analysis was used to evaluate whether FGD6 was an independent prognostic factor for survival of patients with GC. The relationship between FGD6 and overall survival time was explored by the Kaplan–Meier method. In addition, gene set enrichment analysis (GSEA) was performed to investigate the possible biological processes of FGD6.Results: The FGD6 level was significantly overexpressed in GC tissues, compared with adjacent normal tissues. The high expression of FGD6 was related to a high histological grade, stage, and T classification and poor prognosis of GC. Multivariate Cox regression analysis showed that FGD6 was an independent prognostic factor for survival of patients with GC. GSEA identified that the high expression of FGD6 was mainly enriched in regulation of actin cytoskeleton.Conclusion: FGD6 may be a prognostic biomarker for predicting the outcome of patients with GC.
Highlights
Gastric cancer (GC) is the fifth incidence cancer, and it has become the fourth leading cause of cancer deaths in the world, which led to nearly 769,000 deaths in 2020 [1]
By using bioinformatics analysis in TCGA database, we identified that faciogenital dysplasia 6 (FGD6) was increased in GC tissues compared with adjacent non-cancerous tissues, which was verified in paired GC tissues by using GSE63089
The mRNA expression of FGD6 was compared in 30 pairs of tumor and adjacent normal tissues, revealing its expression enhanced in tumor tissues compared with the adjacent normal tissues (p = 0.008) (Figure 1B)
Summary
Gastric cancer (GC) is the fifth incidence cancer, and it has become the fourth leading cause of cancer deaths in the world, which led to nearly 769,000 deaths in 2020 [1]. The prognosis remains poor, and the age-standardized 5-year net survival rate was only 20–40% [2], partially due to the majority of GC cases lacking typical symptoms and being diagnosed at an advanced stage with an experience of postsurgical disease relapse or metastasis [3]. To this end, new methods of diagnosis or novel molecular biomarkers needed to be discovered for prognosis and reliable therapeutic targets of GC patients. The aim of this study was to investigate the prognostic significance of faciogenital dysplasia 6 (FGD6) in gastric cancer (GC)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
